Cartesian Therapeutics, Inc. Expected to Earn FY2027 Earnings of ($7.10) Per Share (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities research analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Cartesian Therapeutics in a research note issued to investors on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($7.10) per share for the year. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($2.10). Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%. The company had revenue of $8.27 million for the quarter.

Other research analysts also recently issued research reports about the stock. SVB Leerink initiated coverage on shares of Cartesian Therapeutics in a report on Tuesday. They set an “outperform” rating and a $39.00 price objective on the stock. HC Wainwright lifted their target price on shares of Cartesian Therapeutics from $2.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Needham & Company LLC initiated coverage on shares of Cartesian Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $42.00 target price on the stock.

Cartesian Therapeutics Trading Up 0.6 %

NASDAQ:RNAC opened at $20.72 on Wednesday. The stock’s 50-day moving average is $19.29. Cartesian Therapeutics has a 52-week low of $11.66 and a 52-week high of $42.60.

Hedge Funds Weigh In On Cartesian Therapeutics

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee purchased a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned approximately 0.98% of Cartesian Therapeutics as of its most recent SEC filing. 86.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Cartesian Therapeutics news, Director Timothy A. Springer bought 21,612 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were acquired at an average cost of $16.20 per share, for a total transaction of $350,114.40. Following the transaction, the director now owns 1,017,228 shares in the company, valued at $16,479,093.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have acquired 22,472 shares of company stock worth $365,981. Corporate insiders own 31.20% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.